Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
Status:
Terminated
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
This study's purpose is to facilitate and expedite the clinical testing of SEVI-D in a
population with advanced GBM that are androgen receptor (AR) positive.
Who is it for? You may be eligible for this study if you have a GBM with
clinical/radiological progression on or following last anticancer therapy.
Study details:
All participants will be screened to confirm if their GBM is AR positive by the study team.
If eligible, participants will receive the medications of Serivteronel and Dexamethasone
(also known as SEVI-D) by oral tablets continuously per cycle (4 weeks). Participants will be
asked to have blood tests, scans, complete questionnaire and regularly meet with the study
doctor and team.
It is hoped this research will demonstrate this treatment could be beneficial for the
treatment of GBM that are known to be human androgen receptor positive.